Topical Antibiotic Prophylaxis for Eyelids

• Status: Completed
• Trial end date: 2019-11-14
• Target enrollment: 0
• Participant gender: All

Summary

The investigators propose a prospective randomized control trial testing the hypothesis that routine topical antibiotic prophylaxis does not significantly reduce the rate of infection after eyelid surgery.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of California, San Francisco
• Treatments: Anti-Bacterial Agents; Anti-Infective Agents; Anti-Infective Agents, Local; Antibiotics, Antitubercular; Bacitracin; Erythromycin; Lubricant Eye Drops

Criteria

Inclusion Criteria:

Patients aged 18 and older who are undergoing various eyelid procedures in an office, ambulatory care center, or operating room including but not limited to:

• blepharoplasty (upper and lower lids);

• ectropion repair;

• entropion repair;

• external dacryocystorhinostomy;

• external levator resection;

• eyelid lesion removal and/or biopsy;

• eyelid reconstruction and defect repair including after Mohs surgery;

• fat pad excision (upper and lower lids);

• gold or platinum weight implantation;

• internal levator resection;

• lateral tarsal strip;

• orbital fracture repair requiring periorbital incisions;

• orbitotomy requiring periorbital incisions;

• tarsorrhaphy;

• wedge excision.

• Patients undergoing repeat procedures will also be included.

Exclusion Criteria:

• Patients aged younger than 18 years old who are undergoing the above eyelid procedures in an office, ambulatory care centers, operating rooms;

• patients undergoing chalazion removal;

• patients who have had previous wound infections at the site of the procedure;

• patients with oral or IV antibiotic use within 10 days prior to procedure;

• patients requiring IV antibiotics during the procedure;

• patients with grossly contaminated or inflamed wounds;

• patients with human or animal bites, patients with wounds resulting from trauma

• patients allergic to all study drug options.